BR0316053A - Uso de um polipeptìdeo de choque térmico e/ou uma sequência de ácido nucléico codificadora, e, método de aliviar a dor - Google Patents

Uso de um polipeptìdeo de choque térmico e/ou uma sequência de ácido nucléico codificadora, e, método de aliviar a dor

Info

Publication number
BR0316053A
BR0316053A BR0316053-0A BR0316053A BR0316053A BR 0316053 A BR0316053 A BR 0316053A BR 0316053 A BR0316053 A BR 0316053A BR 0316053 A BR0316053 A BR 0316053A
Authority
BR
Brazil
Prior art keywords
nucleic acid
acid sequence
heat shock
coding nucleic
alleviating pain
Prior art date
Application number
BR0316053-0A
Other languages
English (en)
Inventor
Anthony Robert Milnes Coates
Original Assignee
Helperby Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helperby Therapeutics Ltd filed Critical Helperby Therapeutics Ltd
Publication of BR0316053A publication Critical patent/BR0316053A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE UM POLIPEPTìDEO DE CHOQUE TéRMICO E/OU UMA SEQuêNCIA DE áCIDO NUCLéICO CODIFICADORA, E, MéTODO DE ALIVIAR A DOR". A presente invenção diz respeito ao uso de um polipeptídeo de choque térmico e/ou uma seq³ência de ácido nucléico codificadora na fabricação de um medicamento para uso no alívio da dor. Em particular, a invenção diz respeito ao uso da chaperonina. A invenção ainda fornece métodos de aliviar a dor usando-se medicamentos que contenham os polipeptídeos de choque térmico.
BR0316053-0A 2002-11-08 2003-11-05 Uso de um polipeptìdeo de choque térmico e/ou uma sequência de ácido nucléico codificadora, e, método de aliviar a dor BR0316053A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0226105.5A GB0226105D0 (en) 2002-11-08 2002-11-08 Pain relief agents
PCT/GB2003/004774 WO2004041304A2 (en) 2002-11-08 2003-11-05 Pain relief agents

Publications (1)

Publication Number Publication Date
BR0316053A true BR0316053A (pt) 2005-09-20

Family

ID=9947469

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316053-0A BR0316053A (pt) 2002-11-08 2003-11-05 Uso de um polipeptìdeo de choque térmico e/ou uma sequência de ácido nucléico codificadora, e, método de aliviar a dor

Country Status (17)

Country Link
US (1) US7744906B2 (pt)
EP (1) EP1562625A2 (pt)
JP (1) JP4607593B2 (pt)
KR (1) KR20050086465A (pt)
CN (1) CN1735427A (pt)
AU (1) AU2003279454B2 (pt)
BR (1) BR0316053A (pt)
CA (1) CA2503964A1 (pt)
CO (1) CO5640148A2 (pt)
GB (2) GB0226105D0 (pt)
IS (1) IS7862A (pt)
MX (1) MXPA05004973A (pt)
NO (1) NO20052216L (pt)
NZ (1) NZ539867A (pt)
RU (1) RU2005117635A (pt)
WO (1) WO2004041304A2 (pt)
ZA (1) ZA200503615B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005204979B2 (en) * 2004-01-16 2010-10-21 Cbio Limited Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
EP1715884B1 (en) * 2004-01-16 2012-03-07 CBIO Limited Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
GB0803369D0 (en) * 2008-02-25 2008-04-02 Helperby Therapeutics Ltd Biological materials and uses thereof
GB201118201D0 (en) * 2011-10-21 2011-12-07 Helperby Therapeutics Ltd Novel peptides
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
GB201700557D0 (en) * 2017-01-12 2017-03-01 Peptinnovate Ltd Novel peptides
AU2017432640B2 (en) 2017-09-22 2023-11-30 Vectura Inc. Dry powder compositions with magnesium stearate
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DK171727B1 (da) 1978-12-22 1997-04-14 Biogen Inc Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
CA2176948C (en) 1993-11-30 2007-05-15 Halle Morton Chaperonin 10
ATE282634T1 (de) * 1993-11-30 2004-12-15 Univ Queensland Chaperonin 10
IT1271074B (it) 1994-11-21 1997-05-26 Italfarmaco Spa Peptidi ad attivita' antiinfiammatoria
PT941315E (pt) * 1996-11-26 2006-06-30 Stressgen Biotechnologies Corp Proteinas de stress contendo proteinas de fusao para induzir respostas imunitarias
EP1042480A1 (en) 1997-12-31 2000-10-11 Stressgen Biotechnologies Corporation Streptococcal heat shock proteins of the hsp60 family
AU2337499A (en) * 1998-01-23 1999-08-09 National Jewish Medical And Research Center Method for treating inflammatory diseases using heat shock proteins
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
JP2003504074A (ja) 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション インビトロでのＴｈ１様応答の誘導
GB0028122D0 (en) 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
GB0803369D0 (en) 2008-02-25 2008-04-02 Helperby Therapeutics Ltd Biological materials and uses thereof

Also Published As

Publication number Publication date
JP4607593B2 (ja) 2011-01-05
KR20050086465A (ko) 2005-08-30
NZ539867A (en) 2008-06-30
CO5640148A2 (es) 2006-05-31
MXPA05004973A (es) 2005-11-23
EP1562625A2 (en) 2005-08-17
IS7862A (is) 2005-05-24
AU2003279454A1 (en) 2004-06-07
US7744906B2 (en) 2010-06-29
JP2006514001A (ja) 2006-04-27
GB2391477A (en) 2004-02-11
US20060252681A1 (en) 2006-11-09
CN1735427A (zh) 2006-02-15
CA2503964A1 (en) 2004-05-21
RU2005117635A (ru) 2006-01-20
AU2003279454B2 (en) 2008-06-19
WO2004041304A2 (en) 2004-05-21
WO2004041304A3 (en) 2004-07-29
NO20052216D0 (no) 2005-05-09
ZA200503615B (en) 2007-02-28
GB2391477B (en) 2004-12-22
GB0325782D0 (en) 2003-12-10
GB0226105D0 (en) 2002-12-18
NO20052216L (no) 2005-08-05

Similar Documents

Publication Publication Date Title
NO20052216L (no) Smertestillende midler
BR0116169A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto.
BR9809445A (pt) Polipeptìdeo compreendendo uma porção imunogênica de um antìgeno de m. tubercolosis, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processos para indução de imunidade protetora em um paciente, processo de detecção de tuberculose em um paciente,e , kit de diagnóstico.
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
NO20062148L (no) Antistoffer som binder interleukin-4-reseptor
BRPI0114927B8 (pt) composição de gel farmacêutica não aquosa para aplicação na pele, e, uso de uma composição
BR0309544A (pt) Preparação farmacêutica contendo oxicodona e naloxona
BR9814276A (pt) Antìgenos de superfìcie
CY1106774T1 (el) Συνθεσεις φαρμακευτικων μεσων με βαση αλατα του τιοτροπιου και αλατα της σαλμετερολης
PT1414816E (pt) Polimorfo estavel da flibanserina, processo tecnico para a sua preparacao e sua utilizacao na preparacao de medicamentos
BRPI0417666A (pt) composição para tratamento oral ou pessoal, método para administrar um material funcional a um sujeito humano ou animal, e, processo para preparar uma composição para tratamento oral ou pessoal
BR9816013A (pt) Proteìna de ligação de interleucina-18
BR0214289A (pt) Composição de bebida compreendendo um composto de boro definido, método de preparação da mesma, kit compreendendo a mesma e uso da mesma na fabricação de um medicamento
DE3688038D1 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
BR0014817A (pt) Imidazo-5-il-aminas bicìclicas, medicamentos que as contém, seu emprego para a preparação de medicamentos e procedimento para sua preparação
BRPI0416365A (pt) métodos para modificar amido ou derivados de amido, e para preparar amido altamente solúvel, e, uso de um reator
BRPI0511624A (pt) anticorpos e moléculas relacionadas que se ligam à proteìnas psca
BR0009781A (pt) Anticorpos antiidiotìpicos contra anticorpos que inibem a ligação de imunoglobulina e ao seu receptor de alta afinidade
BR0207018A (pt) Leptina modificada com imunogenicidade reduzida
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
BR9807332A (pt) Antìgenos de leishmania para utilização na terapia e diagnóstico de leishmaniose
BR0207014A (pt) Antagonista de receptor de interleucina-1 modificada (il-1ra) com imunogenicidade reduzida.
BRPI0415695A8 (pt) agente imunoterápico útil para o tratamento combinado de tuberculose em associação com outras drogas
BR0309085A (pt) Medicamento que contém esteróides e agente anticolinérgico
NO20060637L (no) Autologe selv-toleranse induserende celler av monocytisk opprinnelse og deres anvendelse i farmasoytiske preparater

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A, E 7A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.